Memorial Sloan Kettering Innovation

Memorial Sloan Kettering Innovation is the venture and tech transfer arm of MSK, the New York-based cancer center. The group funds specialized oncology platforms and proprietary cancer care technologies, with declared scope across biotech and pharma therapeutics. AI is not a stated investment theme, though oncology platforms increasingly incorporate computational components.

The fund invests at seed and Series A with $1M to $5M checks. The strategic value lies in access to MSK’s translational expertise, clinical infrastructure, and intellectual property pipeline. U.S. companies in oncology, particularly spinouts or licensees of MSK research, represent the core fit.

Founders should treat MSK Innovation as part technology transfer office and part venture investor. The most effective engagement combines a defined oncology program with a plan to leverage MSK’s clinical and scientific networks. External startups without an existing MSK link should be prepared to articulate why the institution is the right strategic partner. Diligence will emphasize scientific rigor, IP position, and clinical translation plausibility. Limited public information is available about deal cadence.